Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$114.55

1.47 (1.30%)

06:50
07/11/19
07/11
06:50
07/11/19
06:50

Eli Lilly announces Phase 3 Emgality study results published

Eli Lilly announced that the New England Journal of Medicine published Phase 3 study results of Emgality for the treatment of episodic cluster headache. In this study, Emgality reduced the frequency of weekly cluster headache attacks across Weeks 1 to 3 compared to placebo. The FDA approval of Emgality for the treatment of episodic cluster headache in adults in June was based on these results. The study enrolled 106 patients who were randomized 1:1 to receive either 300 mg Emgality or placebo. Prior to enrollment, patients averaged 17.8 weekly cluster headache attacks in the Emgality arm and 17.3 attacks in the placebo arm. Results showed that patients taking Emgality had an average reduction of 8.7 weekly cluster headache attacks across Weeks 1 to 3 compared to a 5.2 average reduction in attacks for placebo. Additionally, 71.4% of patients treated with Emgality had their weekly cluster headache attack frequency reduced by 50% or more at Week 3, the key secondary endpoint, compared to 52.6% of placebo-treated patients. Overall, the safety profile observed in patients with episodic cluster headache treated with Emgality 300 mg monthly is consistent with the safety profile in patients with migraine treated with Emgality 120 mg monthly. Two Emgality-treated patients discontinued double-blind treatment during the episodic cluster headache study because of adverse events.

  • 30

    Jul

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

LLY Eli Lilly
$114.55

1.47 (1.30%)

05/28/19
GSCO
05/28/19
INITIATION
Target $135
GSCO
Buy
Eli Lilly initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Eli Lilly with a Buy rating and $135 price target. The company has new product cycles in four large and growing therapeutic categories - diabetes, cancer, pain and immunology, Flynn tells investors in a research note. He believes investors are underappreciating Eli Lilly's longer-term growth potential in diabetes.
05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.

TODAY'S FREE FLY STORIES

EPD

Enterprise Products

$30.50

0.18 (0.59%)

13:25
07/17/19
07/17
13:25
07/17/19
13:25
Conference/Events
UBS energy analyst to hold an analyst/industry conference call »

Energy Analyst Gershuni…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 31

    Jul

13:25
07/17/19
07/17
13:25
07/17/19
13:25
Conference/Events
Credit Suisse energy analysts to hold an analyst/industry conference call »

Analysts provide a 2Q…

13:25
07/17/19
07/17
13:25
07/17/19
13:25
Conference/Events
The Brookings Institution to hold a discussion »

The Governance Studies at…

FB

Facebook

$202.21

-1.66 (-0.81%)

13:25
07/17/19
07/17
13:25
07/17/19
13:25
Conference/Events
Cowen Washington policy analyst holds an analyst/industry conference call »

Policy Analyst Seiberg,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 24

    Jul

SHW

Sherwin-Williams

$461.39

-6.13 (-1.31%)

13:20
07/17/19
07/17
13:20
07/17/19
13:20
Hot Stocks
Sherwin-Williams, others agree to resolve California lead litigation »

10 California cities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

  • 14

    Aug

GDX

VanEck Vectors Gold Miners ETF

$26.83

0.78 (2.99%)

13:20
07/17/19
07/17
13:20
07/17/19
13:20
Options
Tied put buyers as Gold Miners ETF trades higher »

Tied put buyers as Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/17/19
07/17
13:17
07/17/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$202.58

-1.29 (-0.63%)

, TWTR

Twitter

$37.92

-0.08 (-0.21%)

13:16
07/17/19
07/17
13:16
07/17/19
13:16
On The Fly
#SocialStocks: Facebook says app takeovers benefit users, Twitter tests hiding »

Welcome to…

FB

Facebook

$202.58

-1.29 (-0.63%)

TWTR

Twitter

$37.92

-0.08 (-0.21%)

SNAP

Snap

$14.95

-0.05 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 23

    Jul

  • 24

    Jul

  • 26

    Jul

  • 30

    Jul

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/17/19
07/17
13:16
07/17/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHSP

SharpSpring

$10.30

-1.7 (-14.17%)

13:15
07/17/19
07/17
13:15
07/17/19
13:15
Recommendations
SharpSpring analyst commentary  »

SharpSpring price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

13:15
07/17/19
07/17
13:15
07/17/19
13:15
General news
Treasury Action: bill yields are dipping lower »

Treasury Action: bill…

SHSP

SharpSpring

$10.30

-1.7 (-14.17%)

13:13
07/17/19
07/17
13:13
07/17/19
13:13
Hot Stocks
SharpSpring says added 290 new customers in Q2 »

SharpSpring earlier said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

AMD

AMD

$33.94

0.12 (0.35%)

13:10
07/17/19
07/17
13:10
07/17/19
13:10
Options
Jelly roll in Advanced Micro Devices boosts options volume »

Jelly roll in Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

NFLX

Netflix

$365.99

0.27 (0.07%)

, T

AT&T

$33.44

-0.13 (-0.39%)

13:07
07/17/19
07/17
13:07
07/17/19
13:07
On The Fly
Fly Intel: What to watch in Netflix earnings report »

Netflix (NFLX) is…

NFLX

Netflix

$365.99

0.27 (0.07%)

T

AT&T

$33.44

-0.13 (-0.39%)

CMCSA

Comcast

$44.80

-0.3 (-0.67%)

AAPL

Apple

$204.94

0.54 (0.26%)

DIS

Disney

$143.01

-1.32 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

CSX

CSX

$71.17

-8.4 (-10.56%)

, UNP

Union Pacific

$164.98

-10.12 (-5.78%)

13:01
07/17/19
07/17
13:01
07/17/19
13:01
Downgrade
CSX, Union Pacific, Kansas City Southern, Norfolk Southern rating change at Cascend Securities »

Cascend downgrades four…

CSX

CSX

$71.17

-8.4 (-10.56%)

UNP

Union Pacific

$164.98

-10.12 (-5.78%)

KSU

Kansas City Southern

$117.42

-5.41 (-4.40%)

NSC

Norfolk Southern

$193.18

-13.35 (-6.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

  • 24

    Jul

  • 26

    Aug

  • 13

    Nov

UPS

UPS

$103.54

-2.07 (-1.96%)

12:55
07/17/19
07/17
12:55
07/17/19
12:55
Options
UPS put volume heavy and directionally bearish »

Bearish flow noted in UPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

VRAY

ViewRay

$9.31

0.16 (1.75%)

, VAR

Varian Medical

$134.22

-0.72 (-0.53%)

12:49
07/17/19
07/17
12:49
07/17/19
12:49
Recommendations
ViewRay, Varian Medical analyst commentary at Piper Jaffray »

Competitor recall…

VRAY

ViewRay

$9.31

0.16 (1.75%)

VAR

Varian Medical

$134.22

-0.72 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Sep

TTWO

Take-Two

$118.37

0.88 (0.75%)

12:43
07/17/19
07/17
12:43
07/17/19
12:43
Earnings
Stephens, Cowen up Take-Two price targets ahead of Q1 results »

Take-Two (TTWO) shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 05

    Aug

  • 05

    Sep

  • 13

    Nov

SSRM

SSR Mining

$14.72

0.665 (4.73%)

12:25
07/17/19
07/17
12:25
07/17/19
12:25
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
07/17/19
07/17
12:25
07/17/19
12:25
General news
Treasury Action: the downdraft in European rates has helped pulling Treasury yields lower »

Treasury Action: the…

CAPR

Capricor Therapeutics

$6.39

0.48 (8.12%)

12:25
07/17/19
07/17
12:25
07/17/19
12:25
Conference/Events
Capricor Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

IBM

IBM

$142.94

-0.6 (-0.42%)

12:24
07/17/19
07/17
12:24
07/17/19
12:24
Earnings
Fly Intel: What to watch in IBM's earnings report »

IBM (IBM) is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

AMZN

Amazon.com

$1,999.39

-10.61 (-0.53%)

, QCOM

Qualcomm

$76.74

1.08 (1.43%)

12:23
07/17/19
07/17
12:23
07/17/19
12:23
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have dropped in…

AMZN

Amazon.com

$1,999.39

-10.61 (-0.53%)

QCOM

Qualcomm

$76.74

1.08 (1.43%)

MSFT

Microsoft

$137.11

0.03 (0.02%)

T

AT&T

$33.47

-0.1 (-0.30%)

BAC

Bank of America

$29.47

0.475 (1.64%)

CSX

CSX

$71.11

-8.46 (-10.63%)

ABT

Abbott

$86.33

3.22 (3.87%)

SGEN

Seattle Genetics

$73.43

10.31 (16.33%)

INO

Inovio

$2.65

-0.35 (-11.67%)

NUS

Nu Skin

$37.95

-7.55 (-16.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 06

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 09

    Sep

  • 13

    Nov

KSU

Kansas City Southern

$118.05

-4.78 (-3.89%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
Kansas City Southern rating change  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 13

    Nov

NSC

Norfolk Southern

$194.90

-11.63 (-5.63%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
Norfolk Southern rating change  »

Norfolk Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.